Is Biosynex SA halal to invest in?

According to Musaffa's Shariah screening methodology, Biosynex SA (ALBIO.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Biosynex SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Biosynex SA using these criteria to determine its compliance status.

Can Muslims buy shares of Biosynex SA?

Muslim investors may consider investing in Biosynex SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Biosynex SA classified as NOT HALAL?

Musaffa determines the Shariah status of Biosynex SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Biosynex SA updated?

The Shariah compliance status of Biosynex SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Biosynex SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Biosynex SA?

You can check the latest Shariah compliance status of Biosynex SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Biosynex SA ALBIO.PA

€0.98 €0.05 (4.95%) 1D

Last Updated: May 15, 12:00 AM·XPAR

ALBIO.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 28, 2025

Report Source: 2024 Annual Report

Analyst's Ratings for Biosynex SA (ALBIO.PA)

Based on 9 analysts giving stock ratings to Biosynex SA in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Biosynex SA. Stock Analysis ALBIO.PA

France Health Care Nano Cap Report: 2024 Annual

Biosynex SA engages in the provision of development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company employs 486 full-time employees The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.

Key Statistics of Biosynex SA (ALBIO.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.90€1.02

Today's Open

€0.93

Volume

121.44K

P/E Ratio (TTM)

52 Week Range

€0.46€1.59

Market Cap

14.55M

Avg. Volume

25.89K

Dividend Yield

Financial Metrics & Statements of Biosynex SA (ALBIO.PA)

FAQ's for Biosynex SA (ALBIO.PA)

According to Musaffa’s Shariah screening methodology, Biosynex SA (ALBIO.PA) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.